Monosodium Luminol for Improving Brain Function in Gulf War Illness
Technical Report,30 Sep 2015,29 Sep 2016
The Texas A and M University System College Station United States
Pagination or Media Count:
The goal of this project is to ascertain whether administration of monosodium luminol-GVT MSL-GVT, an antioxidant drug from Bach Pharma in a rat model of Gulf war illness GWI would alleviate mood and memory dysfunction associated with Gulf war illness GWI. Specific Aim 1 studies are focused on quantifying the efficacy of different doses of MSL-GVT for suppressing oxidative stress and inflammation and improving neurogenesis in the hippocampus of rats exposed to GWI-related GWIR chemicals and stress GWI-rats. Specific Aim 2 studies are focused on examining whether long-term administration of an apt dose of MSL-GVT would alleviate mood and memory dysfunction and anxiety in GWI-rats, using a battery of behavioral tests. During the past two years, the experiments pertaining to Specific Aim 1 have been completed. This comprises 1 Exposure of rats to GWIR-chemicals and moderate stress. 2 Oral administration of different doses of MSL-GVT, 4-months after the exposure. 3 Memory and mood function analyses using a battery of behavioral tests. 4 Analyses of oxidative stress and inflammation using biochemical, immunohistochemical and molecular biological studies. The results suggest that administration of higher doses of MSLGVT treatment to GWI-rats for 8 weeks is efficacious for improving memory and mood function with increased hippocampal neurogenesis and suppression of oxidative stress and inflammation.
- Medicine and Medical Research